Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × ivosidenib × Clear all

Phase

Phase 1 3 Phase 3 1 Phase 2 1

Status

Recruiting 7 Active not recruiting 4 Withdrawn 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 610 Cisplatin 568 Gemcitabine 538 Bevacizumab 514 Carboplatin 506 Paclitaxel 495 Docetaxel 483 Radiotherapy 464 Fluorouracil 349 Oxaliplatin 330 Rituximab 315 Capecitabine 301 Doxorubicin 300 Filgrastim 276 Etoposide 274 Irinotecan 266 Dexamethasone 261 Leucovorin 239 Cetuximab 221 pembrolizumab 220 Cytarabine 199 Bortezomib 192 Trastuzumab 186 Erlotinib Hydrochloride 184 Prednisone 182 Vincristine 181 Nivolumab 178 Pemetrexed 172 fludarabine phosphate 162 Temozolomide 162

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed

15 enrolled 14 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡